Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is to evaluated the interruption schedule of NOAC in patients who undergo atrial fibrillation ablation. The investigators will compare the bleeding complications were classified as major and minor bleeding, thromboembolic, vascular complications, Re-admission and increased in the length of hospital stay during the 30-day post-radiofrequency catheter ablation(RFCA) period among patients who interrupt NOAc 24hours before ablation and patients who stop NOAC in the morning of the procedure.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| The group of keep medication NOAC | Experimental | The randomization after scheduling of Ablation at clinic The explanation to stop taking medicine of NOAC 24 hours before the ablation |
|
| The group of stop medication NOAC 1 day | Active Comparator | The randomization after scheduling of ablation at clinic. The explanation to stop taking medicine of NOAC day of ablation |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| novel oral anticoagulant for 30 days | Drug | novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'. |
|
| Measure | Description | Time Frame |
|---|---|---|
| incidence of major bleeding complications | Bleeding complication is assessed by physical examination or laboratory measurement | during 30 days post-AF ablation. |
| Measure | Description | Time Frame |
|---|---|---|
| incidence of thromboembolism | thromboembolism is diagnosed by both clinical situations and image studies combined. | during 30 days post-AF ablation. |
| incidence of minor bleeding | during 30 days post-AF ablation. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Severance Cardiovascular Hospital, Yonsei University Health System | Recruiting | Seoul | 120-752 | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| novel oral anticoagulant for 24 hour | Drug | novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'. |
|
| Re-admission rate related procedure | during 30 days post-AF ablation. |
| length of hospital stay | during 30 days post-AF ablation. |
| incidence of vascular complications | vascular complication is diagnosed by both clinical situations and image studies combined. | during 30 days post-AF ablation. |
| ID | Term |
|---|---|
| D001281 | Atrial Fibrillation |
| ID | Term |
|---|---|
| D001145 | Arrhythmias, Cardiac |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C065145 | N(4)-oleylcytosine arabinoside |
Not provided
Not provided
Not provided